These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21196179)

  • 1. A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm.
    Brzezianska E; Pastuszak-Lewandoska D
    Front Biosci (Landmark Ed); 2011 Jan; 16(2):422-39. PubMed ID: 21196179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Genetic alterations in MAPK and PI3K/Akt signaling pathways and the generation, progression, diagnosis and therapy of thyroid cancer].
    Liu B; Kuang A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Dec; 29(6):1221-5. PubMed ID: 23469561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic markers in differentiated thyroid cancer.
    Gómez Sáez JM
    Curr Genomics; 2011 Dec; 12(8):597-608. PubMed ID: 22654559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.
    Sáez JM
    Anticancer Agents Med Chem; 2013 Mar; 13(3):483-95. PubMed ID: 22583421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
    Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
    Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intracellular signaling mechanisms in thyroid cancer].
    Mondragón-Terán P; López-Hernández LB; Gutiérrez-Salinas J; Suárez-Cuenca JA; Luna-Ceballos RI; Erazo Valle-Solís A
    Cir Cir; 2016; 84(5):434-43. PubMed ID: 27423883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
    Xing M
    Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
    Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
    Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
    Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
    McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Montalto G; Cervello M; Nicoletti F; Fagone P; Malaponte G; Mazzarino MC; Candido S; Libra M; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Milella M; Tafuri A; Cocco L; Evangelisti C; Chiarini F; Martelli AM
    Oncotarget; 2012 Sep; 3(9):954-87. PubMed ID: 23006971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.
    Chen H; Chen W; Zhang X; Hu L; Tang G; Kong J; Wang Z
    Oncol Rep; 2019 Jan; 41(1):570-578. PubMed ID: 30365150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
    Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation.
    Selvaraj N; Budka JA; Ferris MW; Jerde TJ; Hollenhorst PC
    Mol Cancer; 2014 Mar; 13():61. PubMed ID: 24642271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NAD(P)H Quinone Dehydrogenase 1 Ablation Inhibits Activation of the Phosphoinositide 3-Kinase/Akt Serine/Threonine Kinase and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathways and Blocks Metabolic Adaptation in Hepatocellular Carcinoma.
    Dimri M; Humphries A; Laknaur A; Elattar S; Lee TJ; Sharma A; Kolhe R; Satyanarayana A
    Hepatology; 2020 Feb; 71(2):549-568. PubMed ID: 31215069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.
    Hou P; Ji M; Xing M
    Cancer; 2008 Nov; 113(9):2440-7. PubMed ID: 18831514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways.
    Zhou Q; Chen J; Feng J; Xu Y; Zheng W; Wang J
    Mol Cell Biochem; 2017 Nov; 435(1-2):87-95. PubMed ID: 28551845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.